Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J de Castro

Showing results (261-270 of 266) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 266 results.
Thyroid : Official Journal of the American Thyroid Association|December 25, 2015
Ensuring Effective Prevention of Iodine Deficiency DisordersHenry Völzke, Philippe Caron, Lisbeth Dahl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 3, 2016
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapyJ De Castro, J L González-Larriba, S Vázquez, et al.
Cell|December 15, 2010
Functional overlap and regulatory links shape genetic interactions between signaling pathwaysSake van Wageningen, Patrick Kemmeren, Philip Lijnzaad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyF de Marinis, T M Kim, L Bonanno, et al.
Thyroid : Official Journal of the American Thyroid Association|May 29, 2020
Standardized Map of Iodine Status in EuropeTill Ittermann, Diana Albrecht, Petra Arohonka, et al.
Pageof 27

Showing results (261-270 of 266) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 266 results.
Thyroid : Official Journal of the American Thyroid Association|December 25, 2015
Ensuring Effective Prevention of Iodine Deficiency DisordersHenry Völzke, Philippe Caron, Lisbeth Dahl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 3, 2016
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapyJ De Castro, J L González-Larriba, S Vázquez, et al.
Cell|December 15, 2010
Functional overlap and regulatory links shape genetic interactions between signaling pathwaysSake van Wageningen, Patrick Kemmeren, Philip Lijnzaad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyF de Marinis, T M Kim, L Bonanno, et al.
Thyroid : Official Journal of the American Thyroid Association|May 29, 2020
Standardized Map of Iodine Status in EuropeTill Ittermann, Diana Albrecht, Petra Arohonka, et al.
Pageof 27